J. Marc Pipas, M.D.

Senior Medical Director

J. Marc Pipas, M.D.

Senior Medical Director

Dr. Pipas has extensive clinical, research, and leadership expertise built on a long and successful career in clinical oncology at Dartmouth-Hitchcock Medical Center/Norris Cotton Cancer Center, an NCI Comprehensive Cancer Center.  During his academic career, Dr Pipas led the GI Clinical Oncology Group for >10 years, served as Hematology/Oncology Fellowship Director, and was Medical Director for the Office of Clinical Research in the Cancer Center. He has more than 15 years’ experience as a member of Human Subject Protection and Data Monitoring Boards. He has 40 scientific papers and >60 abstracts to his credit and received numerous nominations and awards for teaching and humanism in medicine.

Dr Marc Pipas received his Doctor of Medicine degree from SUNY-HSC at Syracuse in 1989 and completed a residency in Internal Medicine at the Medical University of South Carolina in Charleston.  Following this, he pursued a fellowship in Hematology/Oncology at Dartmouth-Hitchcock Medical Center in New Hampshire and was then invited to become a faculty member at Dartmouth Medical School where he was eventually promoted to Full Professor.

Dr Pipas’ academic career has been followed by extensive clinical development experience in oncology pharmaceuticals and biotech in Cambridge, Massachusetts. During time at Merrimack Pharmaceuticals, Dr Pipas was involved in clinical development work with Onivyde, which was approved by the FDA for pancreatic cancer in late 2015.  Additionally, he was a physician-leader in Merrimack’s sale of Onivyde to Ipsen Pharmaceuticals in 2017.  Following his time at Merrimack, Dr Pipas joined H3 Biomedicine as Executive Medical Director where he led a multicenter, international trial in hepatocellular cancer.  Dr Pipas served as Chief Medical Officer at PanTher Therapeutics from 2021-2022 where he led clinical program activities.

Dr Pipas joined Rho as Senior Medical Director, and he brings a deep understanding of oncologic therapeutics and clinical trial management, as well as a network of research contacts and leadership skills honed by many years of experience.